• Krystal Biotech, Inc. recently reported third-quarter 2025 earnings, revealing net income of US$79.37 million and total revenue of US$97.8 million, reflecting substantial gains compared to the same period last year and continued global commercial expansion of its lead gene therapy, VYJUVEK.
• Key milestones included successful launches of VYJUVEK in Germany, France, and Japan, high US reimbursement approvals, and regulatory steps that broadened the eligible patient population, highlighting progress in both commercial growth and clinical pipeline development.
• We'll explore how this surge in global VYJUVEK adoption and revenue growth influences Krystal Biotech's future investment narrative.

Rare earth metals are the new gold rush. Find out which 38 stocks are leading the charge.

Krystal Biotech Investment Narrative Recap

For investors considering Krystal Biotech, the core thesis has centered on international expansion of its lead gene therapy, VYJUVEK, and the commercial progress highlighted in the latest earnings update underscores this momentum. The strong revenue and earnings reported for the third quarter reflect the positive impact of new market launches, but they do not materially change the biggest risk of near-term revenue volatility linked to ongoing reliance on VYJUVEK and unpredictable patient treatment patterns.

Most relevant to this latest news was the expanded VYJUVEK label in the US, which now enables treatment from birth and increases dosing flexibility. This broadening of the eligible patient base supports key near-term growth catalysts, yet does not eliminate the inherent revenue concentration risk from a single product as pipeline programs remain in development.

On the other hand, it is important for investors to pay close attention to warning signs around international reimbursement delays and the ongoing impact these could have on...

Krystal Biotech's narrative projects $849.4 million in revenue and $485.8 million in earnings by 2028. This requires 33.2% yearly revenue growth and a $339.1 million increase in earnings from $146.7 million today.

Uncover how Krystal Biotech's forecasts yield a $212.50 fair value, a 6% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members’ fair value estimates for Krystal Biotech range widely from US$176 to US$450 based on four distinct views. Amid strong third-quarter results, the business remains highly dependent on VYJUVEK and growth outside the US, making it crucial for you to compare different viewpoints on future performance.

Explore 4 other fair value estimates on Krystal Biotech - why the stock might be worth over 2x more than the current price!

Build Your Own Krystal Biotech Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Krystal Biotech research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Krystal Biotech research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Krystal Biotech's overall financial health at a glance.

No Opportunity In Krystal Biotech?

Our top stock finds are flying under the radar-for now. Get in early:

• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Explore 27 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.